G1

N = 64

G2

N = 136

G3

N = 201

P value

Surgery of the primary tumor, n (%)

42 (66)

94 (69)

171 (85)

<0.001

Surgery of liver metastases, n (%)

9 (14)

24 (17.5)

40 (19.6)

0.3

First line chemotherapy, n (%)

Capecitabine

-

-

26 (12.8)

<0.001

Fufol

49 (76)

-

-

LV5FU2

8 (13)

16 (12)

11 (5)

Folfiri

-

113 (83)

101 (50.3)

Folfox

-

7 (5)

60 (29.6)

Folfirinox

-

-

1 (0.6)

Bevacizumab-Folfiri

-

-

2 (1.1)

Evaluation after 3 cycles, n (%)

OR

21 (33)

68 (50)

116 (57.8)

0.01

CR

5 (8)

16 (11.5)

46 (23.1)

0.001

Evaluation after 6 cycles, n (%)

OR

22 (35)

68 (50)

105 (52.1)

0.049

CR

6 (9)

38 (28)

21 (10.1)

<0.001

Second line chemotherapy, n (%)

17 (26.6)

39 (28.7)

79 (39.3)

Capecitabine

-

5 (14)

18 (22.8)

0.02

LV5FU2

2 (12)

-

2 (2.5)

Folfiri

-

-

29 (36.7)

Folfox

-

18 (46)

27 (34.2)

Bevacizumab-Folfiri

-

-

2 (2.5)

Evaluation after 6 cycles, n (%)

OR

-

-

36 (45.5)

Third line chemotherapy, n (%)

3 (4.7)

5 (3.7)

30 (14.9)

<0.001

Capecitabine

-

-

18 (60)

Folfiri

-

-

5 (16.7)

Folfox

-

-

4 (13.3)

Bevacizumab-Folfiri

-

-

1 (3.3)

Others

-

-

2 (0.6)

Evaluation after 6 cycles, n (%)

OR

-

-

7 (22.2)